Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Net Income (2016 - 2025)

Sunshine Biopharma (SBFM) has disclosed Net Income for 12 consecutive years, with -$883820.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Income rose 26.21% year-over-year to -$883820.0, compared with a TTM value of -$6.0 million through Sep 2025, down 41.81%, and an annual FY2024 reading of -$5.1 million, down 13.94% over the prior year.
  • Net Income was -$883820.0 for Q3 2025 at Sunshine Biopharma, up from -$1.8 million in the prior quarter.
  • Across five years, Net Income topped out at $667116.0 in Q4 2021 and bottomed at -$23.5 million in Q4 2022.
  • Average Net Income over 5 years is -$2.8 million, with a median of -$1.3 million recorded in 2023.
  • The sharpest move saw Net Income crashed 3624.47% in 2022, then skyrocketed 94.68% in 2023.
  • Year by year, Net Income stood at $667116.0 in 2021, then plummeted by 3624.47% to -$23.5 million in 2022, then surged by 94.68% to -$1.3 million in 2023, then tumbled by 72.65% to -$2.2 million in 2024, then skyrocketed by 59.05% to -$883820.0 in 2025.
  • Business Quant data shows Net Income for SBFM at -$883820.0 in Q3 2025, -$1.8 million in Q2 2025, and -$1.2 million in Q1 2025.